Daiichi Sankyo Obtains Approval in Japan for Supplementary Indication of New Quinolone Antibacterial Injection, “Cravit Intravenous Drip Infusion”

1 min read

The FINANCIAL — Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) on September 24 announced that it has obtained approval for partial changes concerning a supplementary indication of their new quinolone antibacterial injections, Cravit Intravenous Drip Infusion Bag 500mg/100mL and Cravit Intravenous Drip Infusion 500mg/20mL (generic name: Levofloxacin Hydrate) to treat bacterial infections of urology, surgery, and gynecology.

These injections are broad-spectrum antibiotics for single-dose daily administration against Gram-positive and -negative bacteria and atypical pathogens. They will be indicated for the treatment of newly approved conditions in addition to respiratory infections, thereby increasing the indications (excluding peritonitis for which an oral agent is not indicated) for switch therapy from injection to oral medicine with the same active ingredient, according to Daiichi Sankyo.

Daiichi Sankyo aims to contribute further in the field of medicine by providing new therapeutic options to patients and medical professionals through its Cravit Intravenous Drip Infusion injections.


Leave a Reply